Fluorescent self-reporting theranostic platforms for tumour therapy: from cytotoxin release monitoring to therapeutic feedback evaluation

, Caspase-3) to enable prompt assessment of tumour cell apoptosis. Finally, we identify key bottlenecks in imaging depth, drug quantification, and pharmacokinetics and propose next-generation design principles to facilitate the clinical translation of adaptive, personalized cancer therapies.